Summary

Dr. Martens plc (LSE:DOCS) is a FTSE 250 and FTSE 350 footwear Brand best known for its iconic boots. The stock is in focus after FY25 results confirmed a total Dividend of 2.55p — flat with FY24 — and a publicly reported Yield/">Dividend Yield of around 3.45%. Share price performance has been challenged but the brand remains globally iconic. This article explains the share price drivers, results and risks for UK investors.

Key takeaways

  • Martens plc is a FTSE 250 and FTSE 350 constituent and one of the world’s most recognisable footwear brands.
  • The Board declared a final FY25 dividend of 1.70p per share, taking the total FY25 dividend including the 0.85p interim to 2.55p (flat versus FY24).
  • The final dividend was paid on 8 October 2025 to shareholders on the register as at 29 August 2025; the next ex-dividend date is 5 March 2026.
  • The dividend yield is reported at around 3.45% based on publicly available data.
  • Share price performance has been challenged versus prior years, though Dr. Martens has outperformed the wider UK Luxury sector and matched the broader UK Market over the past year.

Introduction: Why Dr. Martens shares are in focus on the FTSE 350

Dr. Martens plc (LSE:DOCS) is one of the most globally recognised UK footwear brands and a constituent of the FTSE 250 and the wider FTSE 350. The company designs, develops and sells iconic boots, shoes and accessories under the Dr. Martens brand, with a long heritage dating back to the original 1460 boot. For UK investors monitoring FTSE 350 share price news and UK consumer discretionary stocks, Dr. Martens is one of the most distinctive UK-listed footwear stocks on the London Stock Exchange.

The Dr. Martens share price has been in focus following FY25 results that confirmed a flat total dividend of 2.55p per share and ongoing efforts to stabilise Revenue and profit performance. While the share price has been challenged, the brand’s global recognition and pricing power remain key Long-Term Assets for investors to assess.

Company overview: An iconic UK footwear brand

Dr. Martens is a British footwear brand best known for its iconic boots, including the original 1460 design. The company designs, develops and sells boots, shoes and accessories through a multi-channel approach including direct-to-consumer (DTC) own stores, E-commerce and wholesale to third-party retailers. The brand has a strong global presence, with significant sales across the UK, EMEA, Americas and Asia Pacific.

Dr. Martens trades on the Main Market of the London Stock Exchange under the ticker DOCS and is a constituent of the FTSE 250 and FTSE 350. For UK investors, it is one of the most direct ways to access a UK-listed footwear brand with global reach and an iconic identity.

What happened: FY25 results and a flat total dividend

The most material recent event for Dr. Martens was the publication of FY25 full-year results. According to publicly available announcements, the Board declared a final dividend of 1.70p per share, taking the total FY25 dividend (including the 0.85p interim) to 2.55p — flat versus the FY24 total of 2.55p. The final dividend was paid on 8 October 2025 to shareholders on the register as at 29 August 2025.

The dividend yield is reported at around 3.45% based on publicly available data, with the next ex-dividend date scheduled for 5 March 2026. UK investors should consult Dr. Martens’ Investor relations website for the most current verified revenue, profit, EBITDA and Cash Flow figures.

Why it matters for UK investors

Dr. Martens matters for UK investors as one of the most globally recognised UK consumer brands listed on the LSE. As a FTSE 250 and FTSE 350 constituent, it is held in mid-cap and UK consumer strategies. Its share price serves as a barometer for sentiment on UK and global footwear Demand, brand resilience and the broader luxury and premium consumer environment.

Latest verified update

The most material verified updates for Dr. Martens include the FY25 results, the 2.55p total dividend (flat versus FY24), the final dividend payment on 8 October 2025 and the 5 March 2026 ex-dividend date for upcoming distributions. The FTSE 350 constituent table PDF snapshot showed a price of 66.40p, broadly consistent with the depressed trading range observed during 2025 and 2026. UK investors should consult Dr. Martens’ investor relations communications for the most current results and trading update information.

Share price and investor sentiment

The Dr. Martens share price has been challenged in recent years, reflecting weaker than expected revenue trends in some regions, channel mix dynamics and inventory management. According to publicly available data, Dr. Martens exceeded the UK Luxury industry (which returned -23.8% over the past year) and matched the wider UK Market (which returned around 15% over the past year), suggesting some relative stabilisation.

Sentiment in 2025 and 2026 has been shaped by debate over the long-term recovery potential of the brand, the value of its iconic position and management’s ability to drive growth in DTC and key markets such as the Americas.

Sector and macro context: UK footwear and global consumer trends

Dr. Martens operates in the global footwear sector, which is influenced by fashion cycles, consumer discretionary spending and brand strength. Premium and iconic brands typically have more pricing power and resilience than mass-market peers, but are still exposed to consumer trends and shifting tastes.

Macroeconomic Factors are important. Currency moves between sterling, the US dollar and other currencies affect reported numbers given Dr. Martens’ global revenue mix. Consumer spending in the UK, US and Asia Pacific influences demand and the wholesale order book.

Earnings, dividends and Balance Sheet

According to publicly available data, Dr. Martens’ flat total FY25 dividend of 2.55p reflects a measured Board approach during a period of operational stabilisation. The dividend yield of around 3.45% is competitive within UK consumer discretionary stocks.

Broker, analyst and investor sentiment

Dr. Martens is covered by UK and global Sell-Side analysts focused on consumer brands and footwear. Sentiment in 2025 and 2026 has been mixed, with debate over the pace of recovery, US market dynamics and inventory normalisation.

For specific broker views, investors should consult their own Brokers or platforms such as Reuters, Bloomberg, the Financial Times, MarketWatch and Yahoo Finance UK.

Growth catalysts

Several catalysts could support Dr. Martens’ Investment case. The first is sustained recovery in the Americas, a key strategic market for the brand. The second is continued DTC channel growth, with higher margins than wholesale. The third is product innovation and brand activation that reinforces the iconic status of key franchises such as the 1460 boot.

Risks and uncertainties

Risks include consumer discretionary cyclicality, US wholesale and DTC dynamics, currency Volatility, inventory management, competition from other footwear brands and execution risk on strategic priorities.

What investors should watch next

UK investors monitoring the Dr. Martens share price and FTSE 350 news may want to track interim and full-year results, trading updates, dividend declarations, AGM commentary and any updates on regional performance, particularly in the Americas. Macroeconomic data on UK and global consumer spending, currency moves and footwear sector trends will also influence sentiment.

Conclusion

Dr. Martens is one of the most globally recognised UK consumer brands and a key FTSE 250 and FTSE 350 stock. FY25 results confirmed a flat total dividend of 2.55p, supporting a yield of around 3.45%. Share price performance has been challenged, but the brand’s iconic status provides long-term optionality. For UK investors watching FTSE 350 share price news and UK consumer stocks, Dr. Martens is one of the most distinctive footwear names on the London Stock Exchange.